Bio-Rad has expanded its range of recombinant monoclonal anti-idiotypic antibodies.
Bio-Rad Laboratories recently expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies to include antibodies that are specific to Adcetris (brentuximab vedotin), Cosentyx (secukinumab), and the secukinumab-interleukin 17A (IL-17A) drug-target complex.
Brentuximab vedotin is an antibody drug conjugate used to treat Hodgkin lymphoma, while secukinumab is used to inhibit inflammatory response in several diseases, such as ankylosing spondylitis, psoriasis, and psoriatic arthritis.
According to a company press release from July 12, 2022, these antibodies can be used in the bioanalysis and drug monitoring of brentuximab vedotin, secukinumab, and their biosimilars.
The antibodies for antibrentuximab vedotin and antisecukinumab are approved for in-vitro research purposes, commercial in-vitro testing services to support drug and biosimilar development, and patient monitoring.
Source: Bio-Rad
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.